Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

35.37USD
17 Nov 2017
Change (% chg)

$-0.19 (-0.53%)
Prev Close
$35.56
Open
$35.33
Day's High
$35.49
Day's Low
$35.17
Volume
5,980,857
Avg. Vol
4,868,122
52-wk High
$36.78
52-wk Low
$30.51

Latest Key Developments (Source: Significant Developments)

Pfizer names Albert Bourla chief operating officer
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Pfizer Inc -:Pfizer names Albert Bourla chief operating officer.Pfizer - ‍albert Bourla has been group president of co's innovative health business since beginning of 2016​.Pfizer - ‍effective Jan. 1, 2018, John Young, group president, Pfizer Essential Health becomes group president, Pfizer Innovative Health​.Pfizer - ‍angela Hwang will succeed John Young as group president, Pfizer Essential Health​.  Full Article

Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B.Spark Therapeutics Inc - Co transferring enhanced SPK-9001 manufacturing process to Pfizer.Spark Therapeutics - Co, Pfizer ‍have entered into amendment to their license agreement for SPK-9001.Spark Therapeutics - ‍Subject to terms of amendment, Spark Therapeutics will receive from pfizer an initial $10 million cash payment​.Spark Therapeutics Inc - Will enroll up to five additional participants in current phase 1/2 clinical trial​.Spark - ‍Subject to amendment, to receive from Pfizer up to additional $15 million in potential milestone payments upon completion of transition activities​.Spark Therapeutics - ‍Activities outlined in amended agreement will occur parallel to Pfizer's ongoing preparation to assume responsibility for SPK-9001.  Full Article

Pfizer sees broad interest for consumer health
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Pfizer Inc :Pfizer CEO says expects broad interest from potential acquirers for consumer health business, sees decision in 2018.Pfizer CFO says revenue impact from damage to Puerto Rico plants expected to be insignificant.Pfizer says still believes annual sales of Eucrisa for eczema will eventually exceed $2 billion.  Full Article

Pfizer says qtrly worldwide total lyrica revenue $ 1,150 mln versus $1,049 ln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Pfizer Inc ::Pfizer Inc - qtrly worldwide total lyrica revenue $ 1,150 million versus $1,049 million.Pfizer Inc - qtrly worldwide lipitor revenue $491 million versus $422 million ‍​.Pfizer Inc - qtrly worldwide prevnar family revenue $1,522 million versus $1,536 million.Pfizer Inc - qtrly worldwide ibrance revenue $ 878 million versus $550 million.  Full Article

Pfizer reports Q3 earnings per share of $0.47
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Pfizer Inc :Pfizer reports third-quarter 2017 results.Q3 earnings per share $0.47.Q3 earnings per share view $0.64 -- Thomson Reuters I/B/E/S.Pfizer Inc - ‍narrowed certain 2017 financial guidance ranges​.Qtrly ‍adjusted diluted EPS of $0.67​.Pfizer Inc - qtrly reported revenue $‍13,168​ million versus $13,045 million.Pfizer Inc - ‍raised midpoint of FY adjusted diluted EPS guidance range by $0.03 to a range of $2.58 to $2.62​.Pfizer Inc - qtrly innovative health segment revenue $‍​8,118 million versus $7,332 million.Pfizer Inc - sees FY revenues $52.4 billion‍​ to $53.1 billion‍​.Pfizer Inc - ‍expects that any decision regarding strategic alternatives for consumer healthcare would be made during 2018​.FY2017 earnings per share view $2.56 -- Thomson Reuters I/B/E/S.FY2017 revenue view $52.72 billion -- Thomson Reuters I/B/E/S.Q3 revenue view $13.17 billion -- Thomson Reuters I/B/E/S.  Full Article

ViiV Healthcare announces positive phase 3 results from BRIGHTE study of fostemsavir
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Glaxosmithkline Plc :‍GSK - VIIV HEALTHCARE ANNOUNCES POSITIVE PHASE 3 RESULTS FROM BRIGHTE STUDY OF FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED PATIENTS WITH HIV​.REGULATORY SUBMISSIONS ARE CURRENTLY ANTICIPATED TO TAKE PLACE IN 2019/2020 TIMEFRAME.​.  Full Article

Pfizer reports 5.4 pct passive stake in Rhythm Pharmaceuticals - ‍​SEC filing
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Pfizer Inc ::Pfizer Inc reports 5.4 percent passive stake in Rhythm Pharmaceuticals Inc as of October 10, 2017 - ‍​SEC filing.  Full Article

The Nature's Bounty Co names Mark Gelbert chief scientific officer
Monday, 16 Oct 2017 

Oct 16 (Reuters) - The Nature's Bounty Co [RIC:RIC:CRLYNY.UL]::The Nature's Bounty Co. names Mark Gelbert chief scientific officer.Most recently, Gelbert was senior vice president of Global Research and Development and Switch for Pfizer Consumer Healthcare​.  Full Article

FDA approves Pfizer's Lyrica® CR extended-release tablets CV
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Pfizer Inc :Pfizer Inc - ‍U.S. FDA approves Lyrica CR extended-release tablets CV​.Says ‍Lyrica CR did not receive approval for management of fibromyalgia​.Pfizer inc - ‍lyrica cr did not receive approval for management of fibromyalgia​.Pfizer - in PHN study, 73.6% of patients in Lyrica CR group achieved at least 50% improvement in pain intensity compared with 54.6% in placebo group.  Full Article

Nestle has no comment on Pfizer's consumer healthcare business
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Nestle SA :Nestle declines comment on any interest in Pfizer's consumer healthcare business, says does not comment on rumours as a matter of policy.  Full Article

Endo unit cleared of liability in first testosterone replacement trial

NEW YORK, Nov 16 A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.